Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.
BRCA1/BRCA2
Ashkenazi Jews
cancer risk
genetic testing
lifestyle
population testing
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
22
04
2022
received:
22
09
2021
accepted:
16
05
2022
pubmed:
6
7
2022
medline:
19
10
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
Ashkenazi-Jewish (AJ) population-based BRCA testing is acceptable, cost-effective and amplifies primary prevention for breast & ovarian cancer. However, data describing lifestyle impact are lacking. We report long-term results of population-based BRCA testing on lifestyle behaviour and cancer risk perception. Two-arm randomised controlled trials (ISRCTN73338115, GCaPPS): (a) population-screening (PS); (b) family history (FH)/clinical criteria testing. North London AJ-population. AJ women/men >18 years. prior BRCA testing or first-degree relatives of BRCA-carriers. Participants were recruited through self-referral. All participants received informed pre-test genetic counselling. The intervention included genetic testing for three AJ BRCA-mutations: 185delAG(c.68_69delAG), 5382insC(c.5266dupC) and 6174delT(c.5946delT). This was undertaken for all participants in the PS arm and participants fulfilling FH/clinical criteria in the FH arm. Patients filled out customised/validated questionnaires at baseline/1-year/2-year/3-year follow-ups. Generalised linear-mixed models adjusted for covariates and appropriate contrast tests were used for between-group/within-group analysis of lifestyle and behavioural outcomes along with evaluating factors associated with these outcomes. Outcomes are adjusted for multiple testing (Bonferroni method), with P < 0.0039 considered significant. Lifestyle/behavioural outcomes at baseline/1-year/2-year/3-year follow-ups. 1034 participants were randomised to PS (n = 530) or FH (n = 504) arms. No significant difference was identified between PS- and FH-based BRCA testing approaches in terms of dietary fruit/vegetable/meat consumption, vitamin intake, alcohol quantity/ frequency, smoking behaviour (frequency/cessation), physical activity/exercise or routine breast mammogram screening behaviour, with outcomes not affected by BRCA test result. Cancer risk perception decreased with time following BRCA testing, with no difference between FH/PS approaches, and the perception of risk was lowest in BRCA-negative participants. Men consumed fewer fruits/vegetables/vitamins and more meat/alcohol than women (P < 0.001). Population-based and FH-based AJ BRCA testing have similar long-term lifestyle impacts on smoking, alcohol, dietary fruit/vegetable/meat/vitamin, exercise, breast screening participation and reduced cancer risk perception.
Identifiants
pubmed: 35781768
doi: 10.1111/1471-0528.17253
pmc: PMC9796935
doi:
Substances chimiques
Vitamins
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1970-1980Subventions
Organisme : NHS Innovation Accelerator
ID : PT
Organisme : NIHR Biomedical Research Centre, University College London Hospitals
Organisme : The Eve Appeal
ID : GTCV
Organisme : Medical Research Council
ID : MC_UU_00004/01
Pays : United Kingdom
Informations de copyright
© 2022 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.
Références
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
BJOG. 2022 Nov;129(12):1970-1980
pubmed: 35781768
J Gerontol A Biol Sci Med Sci. 2000 Oct;55(10):M613-7
pubmed: 11034235
PLoS One. 2014 Nov 14;9(11):e112665
pubmed: 25398084
J Genet Couns. 2007 Aug;16(4):433-56
pubmed: 17594133
Cancer Prev Res (Phila). 2020 Aug;13(8):643-648
pubmed: 32409595
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Genet Med. 2018 Nov;20(11):1446-1454
pubmed: 29595811
Fam Cancer. 2009;8(3):241-50
pubmed: 19184534
J R Soc Promot Health. 2007 Jan;127(1):38-44
pubmed: 17319316
J Med Genet. 2016 Jul;53(7):472-80
pubmed: 26993268
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Lifestyle Genom. 2018;11(1):49-63
pubmed: 29635250
Adv Pharm Bull. 2016 Dec;6(4):467-477
pubmed: 28101454
Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):70-5
pubmed: 16434589
J Med Genet. 2018 Aug;55(8):538-545
pubmed: 29622727
Ann Behav Med. 2017 Oct;51(5):718-729
pubmed: 28290066
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:373-412
pubmed: 32315550
J Psychosoc Oncol. 2008;26(3):63-80
pubmed: 19042265
J Genet Couns. 2013 Oct;22(5):565-75
pubmed: 23547022
J Community Genet. 2018 Jan;9(1):1-18
pubmed: 28664264
J Natl Cancer Inst. 2014 Nov 30;107(1):379
pubmed: 25435541
Natl Vital Stat Rep. 2017 Nov;66(6):1-75
pubmed: 29235985
J Natl Cancer Inst. 2014 Nov 30;107(1):380
pubmed: 25435542
Am J Health Promot. 1995 May-Jun;9(5):352-60
pubmed: 10150767
J Am Coll Cardiol. 2017 Mar 7;69(9):1116-1125
pubmed: 28254173
BMJ Open. 2015 Sep 24;5(9):e008705
pubmed: 26408285
JACC Heart Fail. 2017 May;5(5):367-374
pubmed: 28396043
Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12
pubmed: 28690137
BJOG. 2020 Feb;127(3):364-375
pubmed: 31507061
BMJ Open. 2017 Dec 22;7(12):e017675
pubmed: 29275340
J Med Internet Res. 2016 Feb 05;18(2):e30
pubmed: 26851191
Ann Behav Med. 2004 Apr;27(2):107-16
pubmed: 15053018
J Genet Couns. 2007 Aug;16(4):457-68
pubmed: 17619128
BJOG. 2019 May;126(6):784-794
pubmed: 30767407
N Engl J Med. 2011 Feb 10;364(6):524-34
pubmed: 21226570
Aust N Z J Public Health. 2014 Aug;38(4):332-9
pubmed: 24962802
J Genet Couns. 2008 Aug;17(4):314-26
pubmed: 18481164
J Health Popul Nutr. 2007 Mar;25(1):47-61
pubmed: 17615903
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10
pubmed: 25192939
Addiction. 2009 Sep;104(9):1487-500
pubmed: 19686518
Psychol Health. 2011 Sep;26(9):1113-27
pubmed: 21929476
Clin Genet. 2010 Nov;78(5):411-7
pubmed: 20653694
Health Promot Int. 2015 Sep;30(3):736-45
pubmed: 23985248